Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
April 03 2023 - 7:22AM
Business Wire
Accomplished biopharmaceutical executive brings
more than 25 years of experience leading vaccine and antibody
product development for infectious disease indications
Dr. Nabors representing Appili at the World
Vaccine Congress in Washington, D.C.
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the
“Company” or “Appili”), a biopharmaceutical company focused on drug
development for infectious diseases and biodefense, today announced
that it has appointed biopharmaceutical industry veteran Gary
Nabors, Ph.D., to serve as Appili’s Chief Development Officer. Dr.
Nabors joins Appili effective April 3, 2023, and will lead the
advancement of programs through development, regulatory submission
and key commercialization milestones.
“Dr. Nabors brings an exceptional wealth of experience and
established results to Appili, and he will play a critical role in
advancing our programs and our business,” said Dr. Don Cilla,
President and Chief Executive Officer of Appili Therapeutics.
“Gary’s expertise in infectious disease will be instrumental in
driving forward the development of our programs; ATI-1701, a
vaccine for tularemia being funded by the U.S. Government through
IND submission and ATI-1801, a treatment for cutaneous
leishmaniasis (CL), a disfiguring infection of the skin. Both
programs we believe may be eligible to receive FDA Priority Review
Voucher (“PRV”) upon approval and his leadership in progressing
candidates through these next crucial stages will be instrumental
to our growth.”
Dr. Nabors joins Appili from Integrated BioTherapeutics Inc.
(IBT) where, in his role as Executive Vice President and Chief
Development Officer, he was responsible for leading the company’s
vaccine and immunotherapeutic candidates through bioanalytical
development, IND-enabling studies, GMP manufacturing and into
clinical studies. Prior to that he served as President of DynPort
Vaccine Company Inc. (a subsidiary of General Dynamics) where he
was responsible for the overall success of the company, overseeing
P&L responsibility and 800 staff, and establishing the
technical, strategic, and regulatory direction for all projects in
the company’s portfolio.
Over his accomplished 25-year career, Dr. Nabors has also held
progressively senior roles with Sanofi Pasteur, Emergent
BioSolutions, and the National Biodefense Analysis and
Countermeasures Center (NBACC) within the U.S. Department of
Homeland Security. He has played a central role in product
development from pre-clinical stages through to Phase 3, for
development of vaccines and therapeutics for pediatric, adult, and
biodefense markets. He has also managed corporate subsidiaries of
120 employees, served on executive-level management committees and
presented before Food and Drug Administration (FDA) advisory
committees.
“The work being done in anti-infectives at Appili is important
and I am eager to help further establish us as a key player in the
fight against infection,” said Dr Nabors.
Dr. Nabors will be representing Appili at the World Vaccine
Congress, the premier event for R&D and strategic partnering
for the global vaccine industry, in Washington, D.C., from April
3rd to 6th, 2023. Dr. Nabors will be participating in scientific
sessions to identify current trends in vaccine development and to
network with key contacts that Appili may be able to work with to
help advance its programs.
"The World Vaccine Congress provides a great opportunity to
learn how others are progressing their vaccine development
programs, and to have the opportunity to meet with key leaders in
the industry," added Dr. Nabors. "I am looking forward to bringing
this knowledge back to Appili to help us continue driving our
pipeline forward.”
About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical
company that is purposefully built, portfolio-driven, and
people-focused to fulfill its mission of solving life-threatening
infections. By systematically identifying urgent infections with
unmet needs, Appili’s goal is to strategically develop a pipeline
of novel therapies to prevent deaths and improve lives. The Company
is currently advancing a diverse range of anti-infectives,
including a vaccine candidate to eliminate a serious biological
weapon threat, a topical antiparasitic for the treatment of a
disfiguring disease, and a novel easy to use, liquid oral
formulation targeting parasitic and anaerobic infections. Led by a
proven management team, Appili is at the epicenter of the global
fight against infection. For more information, visit
www.AppiliTherapeutics.com.
Forward looking statements
This news release contains “forward-looking statements”,
including with respect to potential PRV eligibility for ATI-1701
and ATI-1801.e. Wherever possible, words such as “may “, “would”,
“could “, “should”, “will,” “anticipate,” “believe,” “plan,”
“expect,” “intend,” “estimate,” “potential for” and similar
expressions have been used to identify these forward-looking
statements. These forward-looking statements reflect the current
expectations of the Company’s management for future growth, results
of operations, performance and business prospects and opportunities
and involve significant known and unknown risks, uncertainties and
assumptions, including, without limitation, those risks listed in
the annual information form of the Company dated June 29, 2022 and
the other filings made by the Company with the Canadian securities
regulatory authorities (which may be viewed at www.sedar.com).
Should one or more of these risks or uncertainties materialize or
should assumptions underlying the forward-looking statements prove
incorrect, actual results, performance or achievements may vary
materially from those expressed or implied by the forward-looking
statements contained in this news release. These factors should be
considered carefully, and prospective investors should not place
undue reliance on the forward-looking statements. The Company
disclaims any intention or obligation to revise forward-looking
statements whether as a result of new information, future
developments or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230401005043/en/
Media: Jenna McNeil, Communications Manager Appili
Therapeutics E: JMcNeil@AppiliTherapeutics.com
Investor Relations: Don Cilla, Pharm.D., M.B.A.,
President and CEO Appili Therapeutics E:
Info@AppiliTherapeutics.com
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
From Aug 2023 to Aug 2024